Patients can develop a cardiomyopathy associated with heart failure and death.
• A single gene defect decreases expression of FXN and may be amenable to therapy.
• A need exists for greater basic and clinical investigations to advance therapies.
Thursday, July 14, 2022
Cardiovascular Research in Friedreich Ataxia
R. Mark Payne; J Am Coll Cardiol Basic Trans Science. null2022, 0 (0); doi:10.1016/j.jacbts.2022.04.005
